We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
5
Jun 2026
A new study to be presented at the SLEEP 2026 annual meeting found that on evenings when adolescents used their smartphone before bedtime more than their own usual, they used their smartphone for longer later that same night, compared with nights when they used their phones less before bedtime.
5
Jun 2026
A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease (CKD) than it is currently recommended for.
5
Jun 2026
Malignant tumors remain a major threat to human health, with conventional therapies and first-generation immune checkpoint inhibitors (ICIs) facing limitations like drug resistance and low response rates.
5
Jun 2026
In 2025, the European Medicines Agency approved two antibodies for Alzheimer's disease: lecanemab (Leqembi, from Biogen) and donanemab (KisunlaTM, from Eli Lilly and Company), both based on immunotherapy (the use of molecules from the immune system to treat diseases).